// App-Quantinova.ai

131P : Circulating tumor cells as liquid biopsy for castration resistant prostate cancer patients treated with cabazitaxel

Researchers

Presenter

  • S.Salvi

Principal Investigators

  • V.Conteduca

  • V.Casadio

  • P.Fici

  • G.Gurioli

  • F.Martignano

  • U.Basso

  • G.Fornarini

  • C.Lolli

  • G.Schepisi

  • S.Testoni

  • D.Calistri

  • U.De Giorgi

Medical Centers

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Medical Oncology Unit, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • IRCCS Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

  • Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Midkine

  • AKT Serine/Threonine Kinase 2

  • Aldehyde dehydrogenase 1

  • Multidrug resistance-associated protein 1

  • Androgen receptor variant 7

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating tumor cells

  • Prostate Stem Cell Antigen

  • Folate Hydrolase 1

  • Solute Carrier Family 22 Member 3

  • Tubulin Beta 3 Class III

  • Vimentin

Drug/Treatment

  • Enzalutamide

  • Cabazitaxel

  • CB-7598

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved